Reports Q4 revenue $19.4M, consensus $18.14M.Michael K. McGarrity, CEO of mdxhealth, commented: “Our fourth quarter and full year 2023 results reflect our continued commitment to commercial execution and operational discipline that has driven significant gross margin expansion across our business. With each passing quarter, we continue to build on our position as a leading precision diagnostics company rooted in our industry-leading technology, focus on the highest quality customer experience, and our unwavering commitment towards improving patient outcomes. We remain well positioned to build upon this success as we actively evaluate multiple, high-growth opportunities that could further strengthen and complement our existing menu. In 2024, we expect to deliver continued topline growth and operating execution that will lead to adjusted EBITDA profitability in the first half of 2025.” Reports Q4revenue $19.4M, consensus $18.14M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MDXH:
- Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results
- Is MDXH a Buy, Before Earnings?
- MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6
- MDxHealth director Jan Pensaert resigns
- MDxHealth Sees FY23 revenue $70.2M, consensus $69.15M
